AbbVie’s (ABBV) Buy Rating Reiterated at Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a report released on Friday,Benzinga reports. They currently have a $249.00 price target on the stock. Guggenheim’s price target points to a potential upside of 19.65% from the company’s current price.

A number of other brokerages have also issued reports on ABBV. UBS Group reduced their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Citigroup cut their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a report on Thursday. Finally, Morgan Stanley increased their price objective on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $252.90.

AbbVie Price Performance

Shares of ABBV stock traded down $3.22 during trading hours on Friday, reaching $208.10. 2,121,099 shares of the company were exchanged, compared to its average volume of 7,178,282. AbbVie has a fifty-two week low of $176.57 and a fifty-two week high of $244.81. The stock’s fifty day moving average is $214.55 and its two-hundred day moving average is $221.60. The company has a market cap of $367.96 billion, a price-to-earnings ratio of 102.50, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period in the prior year, the business earned $2.46 earnings per share. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. On average, research analysts anticipate that AbbVie will post 14.13 earnings per share for the current year.

Insider Activity at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ABBV. Norges Bank acquired a new position in shares of AbbVie in the fourth quarter valued at approximately $5,865,055,000. Wellington Management Group LLP boosted its holdings in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the period. Capital World Investors boosted its holdings in shares of AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after buying an additional 6,736,161 shares during the period. Cardano Risk Management B.V. boosted its holdings in shares of AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after buying an additional 4,908,260 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after buying an additional 4,190,487 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and guidance lift: AbbVie reported better-than-expected Q1 results and raised its 2026 EPS outlook, driven by Skyrizi, Rinvoq and Botox strength — a primary reason for recent upside momentum. AbbVie stock gains, 2026 guidance hike
• Positive Sentiment: Bank of America upgrade: BofA upgraded ABBV to Buy and lifted its price target, signaling growing confidence that Skyrizi/Rinvoq can offset Humira declines and supporting upside sentiment. AbbVie (NYSE:ABBV) Rating Increased to Buy at Bank of America
• Positive Sentiment: Morgan Stanley raised its price target to $278, reinforcing bullish analyst views and adding to momentum for the stock. AbbVie had its price target raised by Morgan Stanley
• Positive Sentiment: Canaccord also lifted its target and maintains a buy stance, adding to the cluster of upward analyst revisions. Canaccord raises price target on AbbVie
• Neutral Sentiment: Competitive positioning: AbbVie laid out how Skyrizi will compete versus J&J’s new Icotyde in plaque psoriasis — shows management focus on defending market share but also highlights an evolving competitive landscape. AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde
• Neutral Sentiment: Corporate outreach/PR: AbbVie awarded a biotech innovators prize (RIME Therapeutics) — positive for long-term innovation positioning but unlikely to move near-term revenue. AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
• Negative Sentiment: Pipeline trimming: While Q1 beat was strong, AbbVie announced it is discontinuing a cancer candidate — a small headwind to R&D optionality that can temper enthusiasm about growth catalysts. AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate
• Negative Sentiment: Analyst estimate tweaks: Erste Group trimmed FY2026/FY2027 EPS estimates slightly, signaling some caution beneath the upbeat headline numbers — contributes to mixed investor sentiment. MarketBeat AbbVie analyst notes (Erste Group)

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.